What is the main business of BBH Biotech Polska?

The main business activity of BBH Biotech Polska focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on June 4, 2014.

Where is the headquarters located?

The headquarters is located at: ul. Irysowa 18, 60-175 Poznań.

Who is on the management board?

The management board consists of: Leszek Broniarek (Member of the Management Board) and Mateusz Marek Hoppe (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 26,500 (approx. $7,158).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What revenue was generated?

In 2024, the company generated total revenue of $28,229, representing a decrease of 13.3% compared to 2023.

Is the company profitable?

No, in 2024 the company was not profitable, reporting a net loss of $2,834. For comparison, in 2023 the loss was $7,215, meaning the company reduced its loss by 62.7%.

BBH Biotech Polskasp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2014-06-04

Share capital

26 500,00 PLN

Registered address

ul. Irysowa 18, 60-175 Poznań, Poland

Website

bbhbiotech.com

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 96 days for 2021).

2025not filed
202430/07/2025
202306/09/2024
202202/08/2023
202119/10/2022
202015/12/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue

This companyUSD 28.23kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD -2.83kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 22.08kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 20.29kMedianUSD 133.19kAverageUSD 3.03m

Industry

Research and experimental development on biotechnology (72.11.Z)Primary
Manufacture of irradiation, electromedical and electrotherapeutic equipment (26.6)
Manufacture of other special-purpose machinery (28.9)

Trademarks

BBH Biotech Polska holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2018.

Mark	Number	Classes	Status	Protected until
APIGEN ROYAL	Z.492934	3, 5, 35, 42, 44	Protected	Nov 21, 2028

Mark	Protected until
APIGEN ROYAL	Nov 21, 2028

Authorized Representatives

Leszek Broniarek – Management Board Member

Mateusz Marek Hoppe – Management Board Member

Manner of representation

To make declarations of will on behalf of the company in matters concerning property and non-property rights and obligations, and to sign on behalf of the company, in the case of a multi-member management board joint representation by at least two members of the company’s management board is required, provided that, in the case of appointment of a President of the Management Board of the company, joint representation by the President of the Management Board of the company and at least one of the other members of the company’s management board is required.

Supervisory board

Marek Włodzimierz Hoppe – Supervisory Board Member

Jakub Jan Tabędzki – Supervisory Board Member

Martyna Tomaszewska – Supervisory Board Member

Ownership

Owner	Shares	Share value	Stake
Leszek Broniarekage 37	53	$715.83	10%
Mateusz Marek Hoppeage 37	53	$715.83	10%
Jakub Jan Tabędzkiage 47	424	$5,726.63	80%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2014-04-07.

BNP Paribas Bank Polska
74 1600 1462 1779 3138 0000 0001
Alior Bank
84 2490 0005 0000 4530 9741 3148

Debt

No entries in the National Debtors Register (KRZ).

Public aid

6 public aid cases recorded, with a total value of $109,555.

Grant date	Purpose	Gross amount	Granting body
May 27, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$24,617$24,617	Polski Fundusz Rozwoju S.A.
Nov 28, 2018	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$830$830	Wielkopolska Agencja Rozwoju Przedsiębiorczości sp. z o.o.
Nov 2, 2018	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$58,117$58,117	Prezes Polskiej Agencji Rozwoju Przedsiębiorczości

European Funds

Start	Project	EU co-financing	Programme
2016-06-01	729194 - Usonipro - ultrasonic technology for bioprocess enhancement	$55,318$55,318	1.1.31 - Horizon 2020

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
GenxoneS.A.	$665,361.35	genxone.eu
Polbiotech Laboratoriumsp. z o.o.	$645,943.81	polbiotech.pl
Relvosp. z o.o.	$120,693.26	relvo.pl
Microblicsp. z o.o.	$122,383.50	microblic.pl
Xenstatssp. z o.o.	$66,774.27	xenstats.com
Immbionicsp. z o.o.	$31,756.23	immbionic.com.pl
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Fungotechsp. z o.o.	$187.68	fungo.tech
Dystrogen TherapeuticsS.A.	–	dystrogen.com
MIMO BiotechP.S.A.	–	mimobiotech.com

Change history

Date	Event
2023-03-29	Address change (Rubież 46 H, 61-612, Poznań → Ul. Irysowa 18, 60-175, Poznań)
2023-03-29	Share capital change (10,500.00 PLN → 26,500.00 PLN)
2016-12-21	Share capital change (10,300.00 PLN → 10,500.00 PLN)
2015-12-10	Share capital change (10,000.00 PLN → 10,300.00 PLN)
2015-07-17	PKD change (Removed: 18.1, 18.2, 26.1, 26.2, 26.3, 26.4, 26.5, 26.7, 26.8, 28.1, 28.2, 28.3, 28.4, 46.1, 46.2, 46.3, 46.4, 46.5, 46.6, 46.9, 47.1, 47.2, 47.3, 47.4, 47.5, 47.6, 47.7, 47.8, 58.1, 58.2, 59.1, 59.2, 62.0, 63.1, 63.9, 68.1, 68.2, 68.3, 70.1, 70.2, 71.1, 72.2, 73.1, 73.2, 74.1, 74.2, 74.3, 77.1, 77.2, 77.3, 85.1, 85.2, 85.3, 85.4, 85.5, 95.1, 95.2; Added: 72.11.Z)

FAQ

Last updated: 2026-04-08